Authors
Latest:
Dr. Burger on the Current Landscape of CAR T-Cell Therapy in CLLJan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsThe combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Latest:
The Impact of Lymphedema in Patients With Head and Neck CancerJan S. Lewin, PhD, professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the impact of lymphedema in patients with head and neck cancer.
Latest:
Dr. Subramanian on the Current Standard of Care in Stage III NSCLCJanakiraman Subramanian, MD, discusses the standard of care in stage III non–small cell lung cancer.
Latest:
Next Steps for KRAS Inhibitors Focus on Tackling ResistanceThe recent approval of sotorasib for the treatment of patients with advanced KRAS G12C–mutant non–small cell lung cancer marks a milestone for cancer therapy.
Latest:
Early Data Make B7-H3 a Checkpoint Contender in Prostate Cancer and BeyondB7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.
Latest:
Dr. Churpek on Gene Mutations in Breast CancerJane E. Churpek, MD, discusses a study that found the inherited mutations in breast cancer genes in African American breast cancer patients were revealed by targeted genomic capture and next-generation sequencing.
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology CareUSPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.
Latest:
Dr Meisel on Perceptions of Patient/Provider Communication in Breast Cancer CareJane L. Meisel, MD, shares information from a study that evaluated patient-reported perceptions of patient-provider communication in breast cancer care.
Latest:
Jane Armer on Lymphedema Symptoms and TreatmentsJane Armer director of ALFP Discusses Lymphedema Symptoms and Treatments
Latest:
Dr. Winter Discusses the ZUMA-7 Trial in DLBCLJane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).
Latest:
Dr. Robertson on Olaparib for Serous Ovarian CancerJane Robertson, MD, Global Product Vice President for olaparib at AstraZeneca, discusses a trial looking at olaparib for patients with serous ovarian cancer.
Latest:
Janet Hampton Explains the Distress Thermometer StudyJanet Hampton from the University of Michigan Health System Cancer Center Explains the Distress Thermometer Study
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician FactorsFor a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Latest:
There's an App for That: Keeping Patients and Physicians on TrackIn a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.
Latest:
Advanced Squamous Carcinoma of the Skin: A Persistent, Growing ChallengeAdvanced SCCS continues to be a treatment challenge given the aggressive behavior of a subset of cases and the absence of randomized clinical trials to provide guidelines for therapy.
Latest:
Dr. Janice Mehnert on Why it's a Challenge to Identify Biomarkers for ImmunotherapyJanice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discusses challenges with identifying effective biomarkers in for immunotherapy agents.
Latest:
Overcoming Burnout as an Oncology FellowJanice Shen, MD, provides advice on how to overcome burnout in order to provide the best care possible for patients with cancer.
Latest:
Dr Tanyi on the Use of Pafolacianine for Intraoperative Molecular Imaging in FRα+ Ovarian CancerJanos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.
Latest:
Dr Weiss on Outcomes With Versamune HPV Plus Pembrolizumab in HPV16+ HNSCCJared Weiss, MD, discusses outcomes with first-line Versamune HPV plus pembrolizumab in HPV16–positive recurrent or metastatic HNSCC.
Latest:
Dr. Mark Discusses an Ultra-Restrictive Opioid Prescription Protocol in Postoperative PatientsJaron Mark, MD, gynecologic oncology fellow, Roswell Park Comprehensive Cancer Center, discusses the implementation of an ultra-restrictive opioid prescription protocol (UROPP) in patients undergoing major gynecologic surgery, which radically decreased dispensed opioids without reducing pain control, during the 2018 Society of Gynecologic Oncology Annual Meeting.
Latest:
Dr. Maciejewski on Impact of Eltrombopag on Expansion of Clones in Refractory Aplastic AnemiaJaroslaw P. Maciejewski, MD, PhD, chair, Department of Translational Hematology and Oncology Research, Cleveland Clinic, discusses the impact of eltrombopag on an expansion of clones with somatic mutations in patients with refractory aplastic anemia.
Latest:
The Potential Utility of CLR 131 in Multiple MyelomaJarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.
Latest:
Looking at the Latest Data in Lung Cancer at ASCO 2023: Dr NaidooOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
